Trade Report: Today: Maxim Group Trims Juno Therapeutics Inc (JUNO) Target Price to $34.00

Today: Maxim Group Trims Juno Therapeutics Inc (JUNO) Target Price to $34.00

Juno Therapeutics Inc (NASDAQ:JUNO) had its price objective cut by Maxim Group from $50.00 to $34.00 in a research report report published on Wednesday. They currently have a buy rating on the biopharmaceutical company’s stock.

JUNO has been the topic of a number of other research reports. BTIG Research reissued a sell rating and issued a $23.00 price target on shares of Juno Therapeutics in a report on Friday, September 9th. Vetr lowered shares of Juno Therapeutics from a strong-buy rating to a buy rating and set a $38.02 price target on the stock. in a report on Tuesday, August 16th. Zacks Investment Research raised shares of Juno Therapeutics from a sell rating to a hold rating in a report on Tuesday, September 6th. Leerink Swann reaffirmed an outperform rating and set a $45.00 target price on shares of Juno Therapeutics in a report on Tuesday, September 27th. Finally, FBR & Co lowered shares of Juno Therapeutics from an outperform rating to a market perform rating and set a $30.00 target price on the stock. in a report on Wednesday, November 23rd. Six research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Juno Therapeutics currently has a consensus rating of Buy and an average target price of $41.13.

Juno Therapeutics (NASDAQ:JUNO) opened at 23.01 on Wednesday. The company has a 50-day moving average of $27.52 and a 200 day moving average of $32.91. The firm’s market cap is $2.36 billion. Juno Therapeutics has a 12-month low of $19.41 and a 12-month high of $57.82.

Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.52) by $0.05. The firm had revenue of $20.80 million for the quarter, compared to analysts’ expectations of $10.98 million. Juno Therapeutics’s revenue was up 1200.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.26) earnings per share. Equities analysts expect that Juno Therapeutics will post ($2.54) EPS for the current fiscal year.

In other news, EVP Robert Azelby sold 12,921 shares of the firm’s stock in a transaction dated Thursday, November 10th. The shares were sold at an average price of $24.14, for a total value of $311,912.94. Following the completion of the sale, the executive vice president now directly owns 48,640 shares of the company’s stock, valued at approximately $1,174,169.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Hans Edgar Bishop sold 23,042 shares of the firm’s stock in a transaction dated Thursday, September 8th. The stock was sold at an average price of $30.06, for a total transaction of $692,642.52. Following the completion of the sale, the chief executive officer now directly owns 2,541,151 shares of the company’s stock, valued at $76,386,999.06. The disclosure for this sale can be found here.

Large investors have recently bought and sold shares of the company. BlackRock Group LTD boosted its stake in Juno Therapeutics by 15.3% in the first quarter. BlackRock Group LTD now owns 34,653 shares of the biopharmaceutical company’s stock valued at $1,320,000 after buying an additional 4,609 shares in the last quarter. State Street Corp boosted its position in shares of Juno Therapeutics by 20.8% in the first quarter. State Street Corp now owns 1,218,468 shares of the biopharmaceutical company’s stock worth $46,412,000 after buying an additional 210,019 shares during the period. Geode Capital Management LLC boosted its position in shares of Juno Therapeutics by 4.2% in the first quarter. Geode Capital Management LLC now owns 423,661 shares of the biopharmaceutical company’s stock worth $16,137,000 after buying an additional 17,205 shares during the period. Creative Planning boosted its position in shares of Juno Therapeutics by 3.1% in the second quarter. Creative Planning now owns 29,740 shares of the biopharmaceutical company’s stock worth $1,143,000 after buying an additional 900 shares during the period. Finally, IBM Retirement Fund acquired a new position in shares of Juno Therapeutics during the second quarter worth about $244,000.

About Juno Therapeutics

Related posts

Leave a Comment